Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raúl Insa

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 24, 2019
Transthyretin stabilization activity of the catechol-<i>O</i>-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study<sup></sup>Josep Gamez, María Salvadó, Núria Reig, et al.
International Journal of Molecular Sciences|June 24, 2022
A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) InhibitorsSeri Jo, Luca Signorile, Suwon Kim, et al.
British Journal of Clinical Pharmacology|December 9, 2022
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's diseaseJosep Gamez, Matilde Calopa, Esteban Muñoz, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|May 24, 2019
Transthyretin stabilization activity of the catechol-<i>O</i>-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study<sup></sup>Josep Gamez, María Salvadó, Núria Reig, et al.
International Journal of Molecular Sciences|June 24, 2022
A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) InhibitorsSeri Jo, Luca Signorile, Suwon Kim, et al.
British Journal of Clinical Pharmacology|December 9, 2022
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's diseaseJosep Gamez, Matilde Calopa, Esteban Muñoz, et al.
Pageof 1